Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy

Correction: Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy

Saved in:

Bibliographic Details
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-11-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/11/e009236corr1.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Targeting IL-33 reprograms the tumor microenvironment and potentiates antitumor response to anti-PD-L1 immunotherapy
by: Yu Bai, et al.
Published: (2024-09-01)

Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in GBM by reprogramming tumor microenvironment
by: Lin Yao, et al.
Published: (2025-04-01)

Inhibition of MBTPS1 enhances antitumor immunity and potentiates anti-PD-1 immunotherapy
by: Yi-Yu Wang, et al.
Published: (2025-04-01)

Reprogramming the immunosuppressive tumor microenvironment results in successful clearance of tumors resistant to radiation therapy and anti-PD-1/PD-L1
by: Debayan Mukherjee, et al.
Published: (2023-12-01)

Dual targeting of tumoral cells and immune microenvironment by blocking the IL-33/IL1RL1 pathway
by: Denggang Fu, et al.
Published: (2025-07-01)

Decitabine co-operates with the IL-33/ST2 axis modifying the tumor microenvironment and improving the response to PD-1 blockade in melanoma
by: Francesco Noto, et al.
Published: (2025-05-01)

Correction: Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy
by: Taijin Shi, et al.
Published: (2025-07-01)

Correction: Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer
Published: (2021-10-01)

Correction: Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
Published: (2025-04-01)

Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1/PD-L1 immunotherapy in hepatocellular carcinoma
by: Valerie Chew, et al.
Published: (2020-10-01)

CDK4/6 inhibitors synergize with radiotherapy to prime the tumor microenvironment and enhance the antitumor effect of anti-PD-L1 immunotherapy in triple-negative breast cancer
by: Wen-Chi Yang, et al.
Published: (2025-08-01)

Expression of SIRPα-Fc by oncolytic virus enhances antitumor efficacy through tumor microenvironment reprogramming
by: Qingzhe Yang, et al.
Published: (2025-02-01)

Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy
by: Yiting Xu, et al.
Published: (2025-05-01)

Activation of Adenosine Phosphate Signaling Promotes Antitumor Immunity in Tumor Microenvironment and Facilitate Immunotherapy
by: Yantao Xu, et al.
Published: (2025-06-01)

IL-19 as a promising theranostic target to reprogram the glioblastoma immunosuppressive microenvironment
by: Gilbert Aaron Lee, et al.
Published: (2025-03-01)

Tumor-intrinsic ENO1 inhibition promotes antitumor immune response and facilitates the efficacy of anti-PD-L1 immunotherapy in bladder cancer
by: Chengquan Shen, et al.
Published: (2025-07-01)

Reprogramming CAR-T cells: Targeting SLC transporters for tumor microenvironment adaptation
by: Beatriz Perucha, et al.
Published: (2025-10-01)

Targeting stemness pathways modulates macrophage polarization and reprograms the tumor microenvironment
by: Austeja Butkute, et al.
Published: (2025-03-01)

Crosstalk between the tumor immune microenvironment and metabolic reprogramming in pancreatic cancer: new frontiers in immunotherapy
by: Taijin Shi, et al.
Published: (2025-04-01)

Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion
by: Qinpei Cheng, et al.
Published: (2025-05-01)

Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors
by: Yi Duan, et al.
Published: (2022-03-01)

The role of immunotherapy in targeting tumor microenvironment in genitourinary cancers
by: Ecem Kalemoglu, et al.
Published: (2025-04-01)

Cancer Immunotherapy Based on the Bidirectional Reprogramming of the Tumor Microenvironment by a “Brakes Off/ Step on the Accelerator” Core‐Shell Manganese Phosphate/siPD‐L1 Modulator
by: Fei Xia, et al.
Published: (2025-06-01)

PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy
by: Jian Cao, et al.
Published: (2025-04-01)

Qingrehuoxue formula enhances anti-PD-1 immunotherapy in NSCLC by remodeling the tumor immune microenvironment via TREM2 signaling
by: Bin-bin Li, et al.
Published: (2025-07-01)

FMRP silencing via siRNA lipid nanoparticles to reprogram the tumor microenvironment and enhance anti-PD-1 efficacy in triple-negative breast cancer
by: Letian Bai, et al.
Published: (2025-08-01)

Stereotactic body radiation therapy (SBRT) increases anti-PD-1 antitumor activity by enhancing the tumor immune microenvironment in mice with metastatic hepatocellular carcinoma
by: Ke Xu, et al.
Published: (2025-06-01)

Metabolic reprogramming and immune microenvironment characteristics in laryngeal carcinoma: advances in immunotherapy
by: Kexin Ma, et al.
Published: (2025-04-01)

IL-11/IL-11R signal inhibition by 9MW3811 remodels immune tumor microenvironment and enhances anti-tumor efficacy of PD-1 blockade
by: Chang Zhang, et al.
Published: (2025-05-01)

Self-assembled PROTACs enable protein degradation to reprogram the tumor microenvironment for synergistically enhanced colorectal cancer immunotherapy
by: Xinchen Lu, et al.
Published: (2025-01-01)

Myeloid cell‐based delivery of IFN‐γ reprograms the leukemia microenvironment and induces anti‐tumoral immune responses
by: Adele Mucci, et al.
Published: (2021-08-01)

Novel phosphatidylserine-binding molecule enhances antitumor T-cell responses by targeting immunosuppressive exosomes in human tumor microenvironments
by: Kunle Odunsi, et al.
Published: (2021-10-01)

Targeting tumor-intrinsic S100 calcium-binding protein A1 augments antitumor immunity and potentiates immunotherapy efficacy
by: Yufeng Guo, et al.
Published: (2025-03-01)

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
by: Yoichiro Narikawa, et al.
Published: (2025-08-01)

Reprogramming of tumor-associated macrophages by metabolites generated from tumor microenvironment
by: Seung Woo Kim, et al.
Published: (2024-12-01)

Eliminating VEGFA+ tumor-associated neutrophils by antibody-drug conjugates boosts antitumor immunity and potentiates PD-1 immunotherapy in preclinical models of cervical cancer
by: Shili Yao, et al.
Published: (2025-02-01)

Tumor-associated macrophages remodel the suppressive tumor immune microenvironment and targeted therapy for immunotherapy
by: Yan Yang, et al.
Published: (2025-05-01)

NK cell-derived artificial extracellular vesicles elicit potent anti-tumor efficacy and tumor microenvironment reprogramming capability
by: Xinyue Zhou, et al.
Published: (2025-05-01)

Anti-galectin-9 therapy synergizes with EGFR inhibition to reprogram the tumor microenvironment and overcome immune evasion
by: Mien-Chie Hung, et al.
Published: (2025-07-01)

Mapping the genetic landscape establishing a tumor immune microenvironment favorable for anti-PD-1 response
by: Daniel A. Skelly, et al.
Published: (2025-05-01)